Get started
Author

Kelsi Willis

Observed institution: Seagen (United States)
ORCID: 0009-0000-1815-6669
Observed ORCID: 0009-0000-1815-6669
OpenAlex ID: A5039686764
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al. · Cancer Research Communications · 37
PDF
Abstract 560: Disitamab vedotin, an investigational HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical cancer models
2023 · Kelsi Willis, Katie Snead, et al. · Cancer Research · 2
Abstract PO1-04-07: Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models
2024 · Kelsi Willis, Renee Hein, et al. · Cancer Research
Abstract 1901: Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy in preclinical urothelial cancer models
2024 · Renee Hein, Kelsi Willis, et al. · Cancer Research
Figure S2 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Data from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Data from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 6 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S2 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 3 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S1 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 2 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
FIGURE 4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S6 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S5 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S6 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S4 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Supplementary Materials and Methods from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Figure S3 from HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
2023 · Devra Olson, Janelle Taylor, et al.
Works count: 28
Citation count: 39
H-index: 2
I10-index: 1
Year
Topic
Type